Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million

#Regulatory

Lund, 2021-06-17


NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, FULLY OR PARTLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OF AMERICA, AUSTRALIA, HONG KONG, CANADA, JAPAN, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA, SOUTH KOREA, OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURE IN ACCORDANCE WITH APPLICABLE LAW.


INSIDE INFORMATION: Xintela AB (publ) (“Xintela” or the “Company”) has, in accordance with the Company's press release yesterday, resolved to issue 11,965,812 new shares at a subscription price of SEK 2.34 (the "Directed Issue"). The Company will receive approximately SEK 28 million through the Directed Issue before deductions for costs related to the Directed Issue. The subscription price in the Directed Issue was determined through an accelerated bookbuilding procedure conducted by Vator Securities. The investors in the Directed Issue consist of a number of Swedish and international professional investors. In addition, Maarten de Chateau, a board member of Xintela, has subscribed for shares corresponding to approximately SEK 3 million in the Directed Issue.

 

The Company intends to use the net proceeds from the Directed Issue for the following activities: (i) approximately 55 percent to finance the stem cell therapy business area, including the start of a clinical phase I/IIa study on  knee osteoarthritis patients (ii) approximately 35 percent to finance the cancer therapy business area, including the continuation of preclinical studies with Xintela's targeted antibodies in models for glioblastoma and triple negative breast cancer (iii) approximately ten percent to finance the Company's operations and strengthen Xintela's working capital.

 

“We are pleased to now have strengthened our financial position, enabling initiation of a clinical phase I/IIa study with our stem cell product XSTEM for the treatment of osteoarthritis and continued preclinical development within our cancer projects. During the year, our GMP-facility for manufacturing of stem cell products has been approved by the Medical Products Agency, we have reported several positive preclinical results and granted patents in our ongoing projects and strengthened our Board of Directors. With this capital injection we can now continue the development towards commercialization of our products ", says CEO Evy Lundgren-Åkerlund.

 

The subscription price for the new shares in the Directed Issue amounts to SEK 2.34 per share and has been determined through an accelerated bookbuilding procedure. The subscription price corresponds to a discount of approximately 19 percent in relation to the 10-day volume weighted average price of the Company’s shares on Nasdaq First North Growth Market up until and including 16 June 2021. Through the Directed Issue, which corresponds to a total of 11,965,812 shares, the Company will receive approximately SEK 28 million before deductions for costs related to the Directed Issue. The investors in the Directed Issue consist of a number of Swedish and international professional investors as well as board member Maarten de Chateau who has subscribed for shares corresponding to approximately SEK 3 million.

 

The Directed Issue will entail a dilution of approximately 13.4 percent of the number of outstanding shares and votes in the Company. Through the Directed Issue, the number of outstanding shares and votes will increase by 11,965,812 from 77,168,209 to 89,134,021. The share capital will increase by SEK 358,974.36, from SEK 2,315,046.27 to SEK 2,674,020.63.

 

The Board of Directors deems, in the light of the accelerated book building procedure completed by Vator Securities as Sole Bookrunner, that the Directed Issue, including the determination of the subscription price, has been determined on market terms. The reasons for the deviation from the shareholders' preferential rights are to raise capital in a time- and cost-effective manner on favorable terms and to diversify the shareholder base with qualified and institutional investors.

 

The Directed Issue has been resolved by the Board of Directors based on the authorization granted by the Annual General Meeting on 7 May 2021. Due to the fact that board member Maarten de Chateau, who belongs to the so-called "LEO circle", has subscribed for shares in the Directed Issue, that part is conditional upon the subsequent approval of the Extraordinary General Meeting. Notice of an Extraordinary General Meeting is announced through a separate press release and contains the Board of Director's complete decision on the part that requires the approval of the Extra General Meeting.

 

In connection with the Directed Issue, board members and members of the Company's management who own shares have undertaken not to sell any shares in the Company for a period of 180 calendar days from the date of admission to trading of the new shares, with customary terms and exemptions from Vator Securities.

 

Advisors
Vator Securities is the Sole Bookrunner and Baker McKenzie Advokatbyrå KB is legal advisor to Xintela in connection with the Directed Issue.

 

This information is such information that Xintela AB (publ) is obliged to make public under the EU Market Abuse Regulation 596/2014. The information was provided by the contact person below for publication at the point in time specified by Xintela’s news distributor beQuoted at the publication of this press release. 

 

The below person may be contacted for further information.

 

Responsible person:
Evy Lundgren-Åkerlund, CEO
Tel: +46 46 275 65 00
E-mail: evy@xintela.se

For more information, please visit: www.xintela.se   

About Xintela 

Xintela develops innovative and patent protected cell therapies and targeted cancer therapies based on the marker technology platform XINMARK. The platform is built on specific cell surface proteins (integrins) and more than 25 years of research and development. Xintela uses the marker technology to select and quality assure stem cells (XSTEM) to develop stem cell therapies for diseases that today lack efficient treatment options, including the joint disease osteoarthritis (OA). Xintela has built an in-house GMP-facility for manufacturing of stem cell products and is preparing a First in Human clinical study on patients with knee OA. In the oncology program, Xintela develops antibody-based therapies for treatment of aggressive tumors including glioblastoma and triple-negative breast cancer. Xintela is listed on Nasdaq First North Growth Market Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North Growth Market is Erik Penser Bank AB, +46 8-463 80 00, certifiedadviser@penser.se.


Important information

The release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions and the recipients of this press release in jurisdictions where this press release has been published or distributed shall inform themselves of and follow such legal restrictions. The recipient of this press release is responsible for using this press release, and the information contained herein, in accordance with applicable rules in each jurisdiction. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in Xintela in any jurisdiction, neither from Xintela nor from someone else.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold within the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. There is no intention to register any securities referred to herein in the United States or to make a public offering of the securities in the United States. The information in this press release may not be announced, published, copied, reproduced or distributed, directly or indirectly, in whole or in part, within or into the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, Switzerland or in any other jurisdiction where such announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than what is required under Swedish law. Actions taken in violation of this instruction may constitute a crime against applicable securities laws and regulations. 

This press release is not a prospectus for the purposes of Regulation (EU) 2017/1129 (the "Prospectus Regulation") and has not been approved by any regulatory authority in any jurisdiction. Xintela has not approved any offer to the public of shares or other securities in any of the EEA countries and no prospectus has been or will be prepared in connection with the Directed Issue. In all EEA Member States, this notice is addressed and is addressed only to qualified investors in that Member State within the meaning of the Prospectus Regulation. 

In the United Kingdom, this press release and any other materials in relation to the securities described herein is only being distributed to, and is only directed at, and any investment or investment activity to which this document relates is available only to, and will be engaged in only with, "qualified investors" (within the meaning of the United Kingdom version of the EU Prospectus Regulation (2017/1129/ EU) which is part of United Kingdom law by virtue of the European Union (Withdrawal) Act 2018) who are (i) persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as "relevant persons"). In the United Kingdom, any investment or investment activity to which this communication relates is available only to, and will be engaged in only with, relevant persons. Persons who are not relevant persons should not take any action on the basis of this press release and should not act or rely on it.

This press release does not identify or suggest, or purport to identify or suggest, the risks (direct or indirect) that may be associated with an investment in the Company’s shares. Any investment decision to acquire or subscribe for shares in connection with the Directed Issue must be made on the basis of all publicly available information relating to the Company and the Company’s shares. Such information has not been independently verified by the Sole Bookrunner. The Sole Bookrunner is acting for the Company in connection with the Directed Issue and no one else and will not be responsible to anyone other than the Company for providing the protections afforded to its clients nor for giving advice in relation to the Directed Issue or any other matter referred to herein.

This press release does not constitute a recommendation for any investors' decisions regarding the Directed Issue. Each investor or potential investor should conduct a self-examination, analysis and evaluation of the business and information described in this press release and any publicly available information. The price and value of the securities can decrease as well as increase. Achieved results do not provide guidance for future results. Neither the contents of the Company's website nor any other website accessible through hyperlinks on the Company's website are incorporated into or form part of this press release.

Forward-looking statements

This press release contains forward-looking statements that reflect the Company's intentions, beliefs, or current expectations about and targets for the Company's and the Group's future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, strategies and opportunities and the markets in which the Company and the Group operates. Forward-looking statements are statements that are not historical facts and may be identified by words such as "believe", "expect", "anticipate", "intend", "may", "plan", "estimate", "will", "should", "could", "aim" or "might", or, in each case, their negative, or similar expressions. The forward-looking statements in this press release are based upon various assumptions, many of which are based, in turn, upon further assumptions. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurances that they will materialize or prove to be correct. Because these statements are based on assumptions or estimates and are subject to risks and uncertainties, the actual results or outcome could differ materially from those set out in the forward-looking statements as a result of many factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this release by such forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are free from errors and readers of this press release should not place undue reliance on the forward-looking statements in this press release. The information, opinions and forward-looking statements that are expressly or implicitly contained herein speak only as of its date and are subject to change without notice. Neither the Company nor anyone else undertake to review, update, confirm or to release publicly any revisions to any forward-looking statements to reflect events that occur or circumstances that arise in relation to the content of this press release, unless it is not required by law or Nasdaq First North Premier Growth Market rule book for issuers. 

Information to distributors

Solely for the purposes of the product governance requirements contained within: (a) EU Directive 2014/65/EU on markets in financial instruments, as amended ("MiFID II"); (b) Articles 9 and 10 of Commission Delegated Directive (EU) 2017/593 supplementing MiFID II; and (c) local implementing measures (together, the "MiFID II Product Governance Requirements"), and disclaiming all and any liability, whether arising in tort, contract or otherwise, which any "manufacturer" (for the purposes of the MiFID II Product Governance Requirements) may otherwise have with respect thereto, the shares in Xintela have been subject to a product approval process, which has determined that such shares are: (i) compatible with an end target market of retail investors and investors who meet the criteria of professional clients and eligible counterparties, each as defined in MiFID II; and (ii) eligible for distribution through all distribution channels as are permitted by MiFID II (the "EU Target Market Assessment"). Solely for the purposes of each manufacturer's product approval process in the United Kingdom, the target market assessment in respect of the shares in the Company has led to the conclusion that: (i) the target market for such shares is only eligible counterparties, as defined in the FCA Handbook Conduct of Business Sourcebook, and professional clients, as defined in Regulation (EU) No 600/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MiFIR"); and (ii) all channels for distribution of such shares to eligible counterparties and professional clients are appropriate (the "UK Target Market Assessment" and, together with the EU Target Market Assessment, the "Target Market Assessment"). Notwithstanding the Target Market Assessment, Distributors should note that: the price of the shares in Xintela may decline and investors could lose all or part of their investment; the shares in Xintela offer no guaranteed income and no capital protection; and an investment in the shares in Xintela is compatible only with investors who do not need a guaranteed income or capital protection, who (either alone or in conjunction with an appropriate financial or other adviser) are capable of evaluating the merits and risks of such an investment and who have sufficient resources to be able to bear any losses that may result therefrom. The Target Market Assessment is without prejudice to the requirements of any contractual, legal or regulatory selling restrictions in relation to the Directed Issue.

For the avoidance of doubt, the Target Market Assessment does not constitute: (a) an assessment of suitability or appropriateness for the purposes of MiFID II or UK MiFIR; or (b) a recommendation to any investor or group of investors to invest in, or purchase, or take any other action whatsoever with respect to the shares in Xintela. 

Each distributor is responsible for undertaking its own target market assessment in respect of the shares in Xintela and determining appropriate distribution channels.


Archive

Below you will find the collected information on Xintela’s press releases, newsletters, diary events, films, media coverage and analyses.

August 27, 2021
Xintela Half-year Report 2021-01-01 - 2021-06-30
July 16, 2021
Xintela announces today that the company has signed a contract with GreenLight Clinical, an Australian Contract Research Organisation (CRO)
July 1, 2021
Xintela incorporates subsidiary
June 17, 2021
Xintela has completed a directed new share issue raising proceeds of approximately SEK 28 million
June 16, 2021
Xintela intends to carry out a directed share issue through an accelerated book building procedure
May 21, 2021
Xintela’s GMP facility approved for manufacturing of cell therapy products
May 20, 2021
Xintela to develop stem cell therapy for difficult-to-heal wounds
May 18, 2021
Xintela's stem cell product XSTEM repairs cartilage damage in preclinical model
May 4, 2021
Targinta recruits Per Norlén as CEO
April 12, 2021
Xintela GMP inspection for manufacturing license completed
April 6, 2021
Xintela reports positive results from preclinical ARDS study and new grant of 2.3 million SEK
March 19, 2021
Xintela gets tissue establishment license
March 17, 2021
Xintela gets patent grant in Europe for XSTEM stem cell product
March 12, 2021
Xintela publishes results from glioblastoma antibody study
February 26, 2021
Year-end report 1 Jan 2020 – 31 Dec 2020
January 7, 2021
Xintela receives Notice of Allowance from USPTO for the treatment of brain tumors
December 21, 2020
Xintela submits manufacturing license application
December 14, 2020
Xintela recruits Jeffrey Abbey to Targinta
December 4, 2020
Arbitral award rendered in favour of Xintela in dispute with former underwriters
December 3, 2020
Xintela Board recommends Maarten de Château as new Board member
November 27, 2020
Xintela publishes interim report for the third quarter of 2020
November 12, 2020
Xintela Board recommends Lars Hedbys as new Board member
October 30, 2020
Status report of Xintela published by BioStock
October 29, 2020
Xintela receives ‘intention to grant’ decision from European Patent Office for stem cell product XSTEM
October 28, 2020
Xintela applies for tissue establishment license
October 26, 2020
Xintela's stem cells show promising results in preclinical ARDS study
August 19, 2020
Xintela strengthens management team
July 29, 2020
Xintela receives Notice of Allowance from USPTO
June 23, 2020
Granted preliminary approval from the European Patent Office for the treatment of brain tumors
June 17, 2020
Xintela develops treatment for aggressive breast cancer
May 8, 2020
Xintela granted 1 million SEK from Vinnova
March 27, 2020
Xintela has been granted 2 million SEK from Vinnova in the call for "Innovation projects in small and medium-sized companies"
February 3, 2020
Positive preclinical results from equine study
December 11, 2019
Positive preclinical results in Xintela’s glioblastoma project
November 29, 2019
Interim report 1 JAN 2019-30 SEP 2019
April 26, 2019
The Board of Xintela AB (publ) announces that Peter Edman has been nominated for election to the Board at the annual general meeting
April 26, 2019
The results of the company's glioblastoma study have now been published in the renowned international scientific journal Cancers.
April 16, 2019
Xintela appoints Sven Kili as Chief Operating Officer
February 27, 2019
Xintela publishes its Year-end Report for 2018
February 15, 2019
Xintela publishes results from stem cell study
January 8, 2019
Xintela broadens and extends patent protection for chondrocyte products and chondrocyte markers
October 25, 2018
The parties intend to jointly develop an ADC therapeutic product with a first focus on glioblastoma
August 29, 2018
Xintela has made the decision to spin out its oncology business to a newly formed subsidiary company, Targinta AB.
August 29, 2018
Sven Kili extends his commitment to Xintela as Chief Medical Officer
August 21, 2018
Xintela announces an update on the company's development programs
August 9, 2018
Xintela today announced that the company's international patent application has been published
July 9, 2018
Xintela signs Letter of Intent with CO.DON
June 28, 2018
Xintela receives MUMS-status for the treatment of osteoarthritis in horses
April 26, 2018
Xintela's GMP facility is completed and being prepared for production and clinical trials
April 17, 2018
Xintela develops unique methods in stem cell therapy for the brain and broadens patent portfolio
March 20, 2018
Xintela prepares for a possible spin-out of its oncology business into a separate company
February 22, 2018
Xintela publishes the Year-end Report for 2017-01-01 - 2017-12-31
December 29, 2017
Xintela licenses human antibody technology for cancer therapy
December 19, 2017
Xintela to collaborate with Japanese CellSeed Inc.
November 13, 2017
Xintela raises 17 million SEK in debt and equity
October 17, 2017
Keld Søndergaard has resigned from the company’s Board of Directors, citing personal reasons.
September 11, 2017
Xintela building own GMP-facility for stem cell production
July 17, 2017
Xintela recruits Liselotte Theorell as Director Product Development and Quality Management
June 22, 2017
Xintela participates in multi-million, government funded initiative to form a cell and gene therapy research center
May 22, 2017
Xintela signs Memorandum of Understanding with the leading European cell therapy company, CO.DON
May 9, 2017
Xintela: Keld Sondergaard nominated as new board member
March 21, 2017
Xintela announces today that Thomas Areschoug has been recruited to the business development team......
February 8, 2017
(In Swedish) Xintela: Insynspersoner och huvudägare avser nyttja teckningsoptioner av serie TO1
January 20, 2017
Xintela reports positive preclinical results in cancer project
January 4, 2017
Xintela´s stem cells show positive treatment effects on cartilage damage in horse study
December 22, 2016
Xintela reports positive results from completed horse study
September 12, 2016
Xintela announces that Rickard Mosell has been recruited as Head of Business Development from October 1, 2016.
August 22, 2016
Xintela today announces that it has settled a dispute and will receive 1,500,000 Swedish Crowns in compensation.
June 23, 2016
Xintela announces that Christer Betsholtz has been engaged as a scientific and strategic advisor
June 1, 2016
Xintela strengthens its organisation wih the appointment of Caroline Ehrencrona as Director Clincial Development and Regulatory Affairs
April 25, 2016
Xintela initiates a study on the treatment of cartilage damage in horses in the USA.
March 16, 2016
Xintela's press releases are currently only published in Swedish. Please contact us if you have further questions.
August 18, 2021
We are now closing in on our next major milestone: initiating clinical trials with the stem cell product XSTEM.
January 26, 2021
Xintela Newsletter December 2020
November 9, 2020
Xintela is targeting several important milestones in the remainder of 2020 and 2021
January 13, 2020
Newsletter December 2019
July 30, 2019
Newsletter July 2019
May 8, 2019
Projects in both regenerative medicine and oncology are making progress and developing very positively.
January 14, 2019
Xintela has worked intensively to connect the company with potential partners and international investors.
January 14, 2019
The following presentation summarises the status of Xintela’s various activities and overall plans for the coming year.
July 17, 2018
Strong first six months for Xintela
March 27, 2018
Large-scale stem cell production paves the way for GMP-certified production
January 5, 2018
Pre-Christmas breakthrough promises an exciting 2018
September 28, 2017
‍Strategic decisions that builds significant value
July 19, 2017
Focusing on Stem Cell Production and Preparations for Clinical Trials
May 16, 2017
On the 21st March 2017, Xintela reported that it was strengthening its Business Development team...
April 5, 2017
A word from the CEO
February 15, 2017
The subscription period for shares supported by warrants has started
December 29, 2016
A Year of Significant Progress
December 14, 2016
Glioblastoma—Xintela's Focus in the Cancer Arena
November 8, 2016
Starting the Autumn with an increased focus on Xintela’s commercial development
October 19, 2016
Since our listing in the Spring, the company has developed in a very positive way and we are on track with the milestones we have set.
August 11, 2016
Confidence in the future with a strong organisation
August 11, 2016
Welcome to Xintela's newsletter
October 25, 2021
BioEurope
25-28 October
October 11, 2021
Cell&Gene on the Mesa
11-20 October
August 30, 2021
BiotechGate partnering
30 August – 3 September
February 27, 2020

BioStock interview with Xintela's CMO and board member Sven Kili.

August 30, 2018

BioStock was given the opportunity to interview Sven Kili in connection with his visit to Sweden for board and strategy work in Xintela.

February 9, 2017

Dr. Marcus Keep comments on Xintelas glioblastoma project.

January 31, 2017

Xintelas Chairman of the board and strategic advisor Greg Batcheller, tells us more about Xintelas potential and prospects.

January 30, 2017

Dr. Lisa Fortier at Cornell University, New York is interviewed by BioStock about Xintelas positive results in horse study.

December 28, 2016

In the following video interview, Karin explains her role at Xintela and what she considers to be Xintela’s primary strengths.

December 13, 2016

See the interview with Claes Post, member of the board in Xintela. The interview is in swedish with english subtitles.

March 24, 2016

See the interview with Sven Kili, member of the board in Xintela. The interview is in English (introduction is in Swedish).

March 22, 2016

See an interview with Xintela's CEO Evy Lundgren-Åkerlund, after the listing ceremony at Nasdaq First North.

March 15, 2016

Investor presentation from Lund - Jan 27

January 14, 2016

Interview with Xintelas CEO

November 9, 2020
BioStock: Xintela’s CEO comments on the positive patent notice
June 22, 2017
Xintela covered in GEN regarding its participation in multi-million, government funded initiative to form a...
March 2, 2017
Xintela covered in Horsetalk.co.nz regarding that its stem cells are safe for use in horses
March 23, 2016
(Article in Swedish) Grundare av Xintela ser notering som viktig milstolpe
March 23, 2016
(Article in Swedish) Xintela tar behandling av ledskador och cancer till First North.
March 23, 2016
(Article in Swedish) Xintela covered in Life Science Sweden
February 24, 2016
(Article in Swedish) Rapidus: Xintela på väg till First North
July 14, 2021
Xintela, backed by its integrin biomarker technology platform XINMARK, is a potential disrupter
November 9, 2020
A status report of the Xintela has been published by Biostock
April 12, 2018
Read the full analysis here
Top